IMO Russia will jump on Brilacidin long before the FDA if possible and if they exist doesn't go against clinical trial rules of secrecy or letting the host country of the drug make the first announcement.

Another poster on another site said the new Russian testing center was a main focal point for Russian TB patients and Russia may be wanting to see how Brilacidin's anti-inflammatory properties works to help CV19 patients that also have lung problems due to TB.

Bottom line is this trial's data could also open many doors in helping to jump start research into Brilacidin and respiratory problems.

Good things from start to finish.